Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Gynecology

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    March 2019
  1. GORANOVA T, Ennis D, Piskorz AM, Macintyre G, et al
    Correction: Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.
    Br J Cancer. 2019 Mar 13. pii: 10.1038/s41416-019-0433.
    PubMed     Text format     Abstract available


    February 2019
  2. FROELING FEM, Ramaswami R, Papanastasopoulos P, Kaur B, et al
    Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours.
    Br J Cancer. 2019 Feb 22. pii: 10.1038/s41416-019-0402.
    PubMed     Text format     Abstract available


  3. WESTERGAARD MCW, Andersen R, Chong C, Kjeldsen JW, et al
    Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.
    Br J Cancer. 2019 Feb 5. pii: 10.1038/s41416-019-0384.
    PubMed     Text format     Abstract available


    January 2019
  4. LEE CK, Scott C, Lindeman GJ, Hamilton A, et al
    Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Br J Cancer. 2019 Jan 17. pii: 10.1038/s41416-018-0349.
    PubMed     Text format     Abstract available


    December 2018
  5. SINGEL KL, Grzankowski KS, Khan ANMNH, Grimm MJ, et al
    Mitochondrial DNA in the tumour microenvironment activates neutrophils and is associated with worse outcomes in patients with advanced epithelial ovarian cancer.
    Br J Cancer. 2018 Dec 6. pii: 10.1038/s41416-018-0339.
    PubMed     Text format     Abstract available


    November 2018
  6. GIANNAKEAS V, Cadarette SM, Ban JK, Lipscombe L, et al
    Denosumab and breast cancer risk in postmenopausal women: a population-based cohort study.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0225.
    PubMed     Text format     Abstract available


    October 2018
  7. WORTMAN BG, Creutzberg CL, Putter H, Jurgenliemk-Schulz IM, et al
    Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
    Br J Cancer. 2018 Oct 25. pii: 10.1038/s41416-018-0310.
    PubMed     Text format     Abstract available


  8. FRIEDLANDER M, Matulonis U, Gourley C, du Bois A, et al
    Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0271.
    PubMed     Text format     Abstract available


  9. HODGSON DR, Dougherty BA, Lai Z, Fielding A, et al
    Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
    Br J Cancer. 2018 Oct 24. pii: 10.1038/s41416-018-0274.
    PubMed     Text format     Abstract available


  10. ARROYO-MUHR LS, Lagheden C, Hultin E, Eklund C, et al
    Human papillomavirus type 16 genomic variation in women with subsequent in situ or invasive cervical cancer: prospective population-based study.
    Br J Cancer. 2018 Oct 22. pii: 10.1038/s41416-018-0311.
    PubMed     Text format     Abstract available


  11. PATEL JN, Braicu I, Timms KM, Solimeno C, et al
    Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
    Br J Cancer. 2018 Oct 15. pii: 10.1038/s41416-018-0268.
    PubMed     Text format     Abstract available


  12. NIEMI RJ, Braicu EI, Kulbe H, Koistinen KM, et al
    Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
    Br J Cancer. 2018 Oct 8. pii: 10.1038/s41416-018-0270.
    PubMed     Text format     Abstract available


  13. WANG P, Magdolen V, Seidl C, Dorn J, et al
    Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.
    Br J Cancer. 2018 Oct 5. pii: 10.1038/s41416-018-0260.
    PubMed     Text format     Abstract available


    August 2018
  14. TSIBULAK I, Wieser V, Degasper C, Shivalingaiah G, et al
    BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.
    Br J Cancer. 2018 Aug 15. pii: 10.1038/s41416-018-0217.
    PubMed     Text format     Abstract available


  15. AOKI Y, Ochiai K, Lim S, Aoki D, et al
    Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
    Br J Cancer. 2018 Aug 3. pii: 10.1038/s41416-018-0206.
    PubMed     Text format     Abstract available


    July 2018
  16. GADDUCCI A, Grosso F, Scambia G, Raspagliesi F, et al
    A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0190.
    PubMed     Text format     Abstract available


  17. CARTER JH, Deddens JA, Mueller G, Lewis TG, et al
    Transcription factors WT1 and p53 combined: a prognostic biomarker in ovarian cancer.
    Br J Cancer. 2018 Jul 30. pii: 10.1038/s41416-018-0191.
    PubMed     Text format     Abstract available


  18. KOMMOSS FK, Karnezis AN, Kommoss F, Talhouk A, et al
    L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
    Br J Cancer. 2018 Jul 27. pii: 10.1038/s41416-018-0187.
    PubMed     Text format     Abstract available


  19. GHAFFARI A, Peterson N, Khalaj K, Vitkin N, et al
    STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer.
    Br J Cancer. 2018 Jul 26. pii: 10.1038/s41416-018-0188.
    PubMed     Text format     Abstract available


  20. HILLIARD C
    Comment on 'Dairy, calcium, vitamin D, and ovarian cancer risk in African-American women'.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0166.
    PubMed     Text format    


  21. QIN B, Peres LC, Schildkraut JM, Bandera EV, et al
    Reply to 'Comment on 'Dairy, calcium, vitamin D and ovarian cancer risk in African-American women''.
    Br J Cancer. 2018 Jul 2. pii: 10.1038/s41416-018-0163.
    PubMed     Text format    


    June 2018
  22. RUSCITO I, Cacsire Castillo-Tong D, Vergote I, Ignat I, et al
    Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
    Br J Cancer. 2018 Jun 29. pii: 10.1038/s41416-018-0157.
    PubMed     Text format     Abstract available


  23. SHI T, Jiang R, Yu J, Yang H, et al
    Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0036.
    PubMed     Text format     Abstract available


  24. VIALATTE DE PEMILLE C, Berzero G, Small M, Psimaras D, et al
    Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
    Br J Cancer. 2018 Jun 14. pii: 10.1038/s41416-018-0125.
    PubMed     Text format     Abstract available


    May 2018
  25. NEUMEYER S, Banbury BL, Arndt V, Berndt SI, et al
    Mendelian randomisation study of age at menarche and age at menopause and the risk of colorectal cancer.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0108.
    PubMed     Text format     Abstract available


  26. DERKS-SMEETS IAP, Schrijver LH, de Die-Smulders CEM, Tjan-Heijnen VCG, et al
    Ovarian stimulation for IVF and risk of primary breast cancer in BRCA1/2 mutation carriers.
    Br J Cancer. 2018 May 1. pii: 10.1038/s41416-018-0139.
    PubMed     Text format     Abstract available


    March 2018
  27. LAGHEDEN C, Eklund C, Lamin H, Kleppe SN, et al
    Nationwide comprehensive human papillomavirus (HPV) genotyping of invasive cervical cancer.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0053.
    PubMed     Text format     Abstract available


  28. DIXON-SUEN SC, Nagle CM, Thrift AP, Pharoah PDP, et al
    Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
    Br J Cancer. 2018 Mar 20. pii: 10.1038/s41416-018-0011.
    PubMed     Text format     Abstract available


  29. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Text format     Abstract available


    January 2018
  30. GOEDERT JJ, Hua X, Bielecka A, Okayasu I, et al
    Postmenopausal breast cancer and oestrogen associations with the IgA-coated and IgA-noncoated faecal microbiota.
    Br J Cancer. 2018 Jan 23. pii: bjc2017435. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  31. VERDOODT F, Kjaer SK, Dehlendorff C, Friis S, et al
    Aspirin use and ovarian cancer mortality in a Danish nationwide cohort study.
    Br J Cancer. 2018 Jan 9. pii: bjc2017449. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  32. LAM JUH, Elfstrom KM, Ejegod DM, Pedersen H, et al
    High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders.
    Br J Cancer. 2018;118:138-144.
    PubMed     Text format     Abstract available


    December 2017
  33. PLAYDON MC, Coburn SB, Moore SC, Brinton LA, et al
    Alcohol and oestrogen metabolites in postmenopausal women in the Women's Health Initiative Observational Study.
    Br J Cancer. 2017 Dec 12. pii: bjc2017419. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  34. SEAMON LG, Java JJ, Monk BJ, Penson RT, et al
    Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.
    Br J Cancer. 2017 Nov 28. pii: bjc2017400. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  35. HALLE MK, Tangen IL, Berg HF, Hoivik EA, et al
    HER2 expression patterns in paired primary and metastatic endometrial cancer lesions.
    Br J Cancer. 2017 Nov 23. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  36. KAWAKITA D, Lee YA, Gren LH, Buys SS, et al
    The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. MARKOVINA S, Wang S, Henke LE, Luke CJ, et al
    Serum squamous cell carcinoma antigen as an early indicator of response during therapy of cervical cancer.
    Br J Cancer. 2017 Nov 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  38. HEINONEN HR, Mehine M, Makinen N, Pasanen A, et al
    Global metabolomic profiling of uterine leiomyomas.
    Br J Cancer. 2017 Oct 26. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  39. POYNTER JN, Richardson M, Roesler M, Krailo M, et al
    Family history of cancer in children and adolescents with germ cell tumours: a report from the Children's Oncology Group.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  40. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  41. WANG X, Zhu Q, Lin Y, Wu L, et al
    Crosstalk between TEMs and endothelial cells modulates angiogenesis and metastasis via IGF1-IGF1R signalling in epithelial ovarian cancer.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  42. POLMAN NJ, Veldhuijzen NJ, Heideman DAM, Snijders PJF, et al
    HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    August 2017
  43. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  44. BELGIOVINE C, Bello E, Liguori M, Craparotta I, et al
    Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models.
    Br J Cancer. 2017;117:628-638.
    PubMed     Text format     Abstract available


  45. BURGER EA, Pedersen K, Sy S, Kristiansen IS, et al
    Choosing wisely: a model-based analysis evaluating the trade-offs in cancer benefit and diagnostic referrals among alternative HPV testing strategies in Norway.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: